GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection
GlaxoSmithKline plc (GSK, NYSE: GSK) announced a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT) for USD 58.00...
RAPT Therapeutics
RAPT Therapeutics Secures Ex-China Rights to Jemincare Group’s Anti-IgE Antibody JYB1904
US-based biopharmaceutical company RAPT Therapeutics Inc. (NASDAQ: RAPT) has announced that it has obtained the...